
MK-4827 tosylate
CAS No. 1038915-73-9
MK-4827 tosylate( Niraparib tosylate | MK 4827 tosylate | MK4827 tosylate )
Catalog No. M10196 CAS No. 1038915-73-9
A highly potent PARP inhibitor with IC50 of 3.8 nM/2.1 nM for PARP1/PARP2.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 34 | In Stock |
![]() ![]() |
5MG | 55 | In Stock |
![]() ![]() |
10MG | 77 | In Stock |
![]() ![]() |
25MG | 107 | In Stock |
![]() ![]() |
50MG | 135 | In Stock |
![]() ![]() |
100MG | 219 | In Stock |
![]() ![]() |
500MG | 534 | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameMK-4827 tosylate
-
NoteResearch use only, not for human use.
-
Brief DescriptionA highly potent PARP inhibitor with IC50 of 3.8 nM/2.1 nM for PARP1/PARP2.
-
DescriptionA highly potent PARP inhibitor with IC50 of 3.8 nM/2.1 nM for PARP1/PARP2; inhibits PARP activity with EC50=4 nM in a whole cell assay, and inhibits proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC50 in the 10?100 nM range; well tolerated in vivo and demonstrates efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer.Ovarian Cancer Approved(In Vitro):Niraparib (MK-4827) inhibits PARP activity with EC50=4 nM and EC90=45 nM in a whole cell assay. MK-4827 inhibits proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC50 in the 10?100 nM range. MK-4827 displays excellent PARP 1 and 2 inhibition with IC50=3.8 and 2.1 nM, respectively, and in a whole cell assay. To validate that Niraparib (MK-4827) inhibits PARP in these cell lines, A549 and H1299 cells are treated with 1 μM Niraparib (MK-4827) for various times and measured PARP enzymatic activity using a chemiluminescent assay. The results show that Niraparib (MK-4827) inhibits PARP within 15 minutes of treatment reaching about 85% inhibition in the A549 cells at 1 h and about 55% inhibition at 1 h for the H1299 cells.(In Vivo):Niraparib (MK-4827) is well tolerated and demonstrates efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer. Niraparib (MK-4827) is well tolerated in vivo and demonstrates efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer. Niraparib (MK-4827) is characterized by acceptable pharmacokinetics in rats with plasma clearance of 28 (mL/min)/kg, very high volume of distribution (Vdss=6.9 L/kg), long terminal half-life (t1/2=3.4 h), and excellent bioavailability, F=65%. Niraparib (MK-4827) enhances radiation response of p53 mutant Calu-6 tumor in both cases, with the single daily dose of 50 mg/kg being more effective than 25 mg/kg given twice daily.
-
In Vitro——
-
In Vivo——
-
SynonymsNiraparib tosylate | MK 4827 tosylate | MK4827 tosylate
-
PathwayCell Cycle/DNA Damage
-
TargetPARP
-
RecptorPARP1|PARP2
-
Research AreaCancer
-
IndicationOvarian Cancer
Chemical Information
-
CAS Number1038915-73-9
-
Formula Weight492.5899
-
Molecular FormulaC26H28N4O4S
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 490 mg/mL
-
SMILESCC1=CC=C(C=C1)S(=O)(=O)O.C1CC(CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N
-
Chemical Name2H-Indazole-7-carboxamide, 2-[4-(3S)-3-piperidinylphenyl]-, 4-methylbenzenesulfonate (1:1)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Jones P, et al. J Med Chem. 2009 Nov 26;52(22):7170-85.
2. Bridges KA, et al. Oncotarget. 2014 Jul 15;5(13):5076-86.
3. Mirza MR, et al. N Engl J Med. 2016 Dec 1;375(22):2154-2164.
molnova catalog



related products
-
E7449
E7449 (2X-121) is a potent, orally bioavailable, brain penetrable dual inhibitor of PARP1/2 and TNKS1/2 with IC50 of 2.0/1.0 nM (PARP1/2), 50-100 nM (TNKS1/2).
-
D-Arabinose
Inexpensive starting material for chiral synthesis.
-
PARP1/2/TNKS1/2-IN-1
PARP1/2/TNKS1/2-IN-1 is a multi-target inhibitor of PARP-1, PARP-2, TNKS1, and TNKS2, with potential anti-tumor activity that induces apoptosis.